Chemistry:Bevantolol

From HandWiki
Short description: Chemical compound
Bevantolol
Bevantolol.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
Chemical and physical data
FormulaC20H27NO4
Molar mass345.439 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  (verify)

Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker.[1][2] It was discovered and developed by Warner-Lambert[3] but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?"[4] (As of 2016) it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.[5]

References

  1. "Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris". Drugs 35 (1): 1–21. January 1988. doi:10.2165/00003495-198835010-00001. PMID 2894292. 
  2. "Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions". Journal of Clinical Pharmacology 27 (7): 450–60. July 1987. doi:10.1002/j.1552-4604.1987.tb03049.x. PMID 2888789. 
  3. McPherson, Edwin M. (2007). Pharmaceutical Manufacturing Encyclopedia. (3rd ed.). Burlington: Elsevier. pp. 618–619. ISBN 9780815518563. https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA618. 
  4. "Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds". Pink Sheet. 30 January 1989. https://pink.pharmamedtechbi.com/PS015015/WARNERLAMBERT-PIPELINE-NARROWED-TO-40-ACTIVE-RESEARCH-COMPOUNDS-ACCUPRIL-QUINAPRIL-NDA-SUBMITTED-JAN-25-80-MIL-BUDGETTED-FOR-CV-WORK-IN-1989. 
  5. "Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension". The Cochrane Database of Systematic Reviews 3 (4): CD007451. March 2016. doi:10.1002/14651858.CD007451.pub2. PMID 26961574.